Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine.

Pei, Jin; Zhang, Chuanbo; Gokhale, Prafulla C; Rahman, Aquilur; Dritschilo, Anatoly; Ahmad, Imran; Kasid, Usha N

Pei, Jin; Zhang, Chuanbo; Gokhale, Prafulla C; Rahman, Aquilur; Dritschilo, Anatoly; Ahmad, Imran; Kasid, Usha N.

Affiliation

Pei J; Department of Radiation Medicine, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA.

Anticancer Drugs ; 15(3): 243-53, 2004 Mar.

Article in En | MEDLINE | ID: mdl-15014358

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/administration & dosage; Deoxycytidine/analogs & derivatives; Oligonucleotides, Antisense/administration & dosage; Proto-Oncogene Proteins c-raf/administration & dosage; Xenograft Model Antitumor Assays/methods; Animals; Cell Line, Tumor; Cisplatin/administration & dosage; Deoxycytidine/administration & dosage; Docetaxel; Epirubicin/administration & dosage; Female; Humans; Liposomes; Male; Mice; Mice, Nude; Mitoxantrone; Proto-Oncogene Proteins c-raf/biosynthesis; Taxoids/administration & dosage; Gemcitabine

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Oligonucleotides, Antisense / Proto-Oncogene Proteins c-raf / Xenograft Model Antitumor Assays / Deoxycytidine Limits: Animals / Female / Humans / Male Language: En Journal: Anticancer Drugs Journal subject: ANTINEOPLASICOS Year: 2004 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links